Does Dr. ELIZABETH SWANSON have financial conflicts of interest?

Dr. ELIZABETH SWANSON (M.D.) has received a total of $2,303,952 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $2,286,897 in personal promotional payouts (consulting, meals, travel) and $17,055 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ELIZABETH SWANSON?

According to CMS Open Payments data, Dr. ELIZABETH SWANSON received funding from GENZYME CORPORATION ($475,050), REGENERON HEALTHCARE SOLUTIONS ($473,033), and LILLY USA ($314,016).

Does Dr. ELIZABETH SWANSON receive research grants or speaking fees?

Dr. ELIZABETH SWANSON has received $2,286,897 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $17,055 in clinical research grants.

DR. ELIZABETH SWANSON

M.D.Real-Time Hydrated

Specialty: Dermatology, Pediatric Dermatology

Practice Location: MERIDIAN, ID 83642

NPI Number: 1174596951

LIFETIME INDUSTRY VALUE

$2,303,952

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. SWANSON is a verified Dermatology, Pediatric Dermatology practitioner based in MERIDIAN, ID.

Between 2021 and 2025, Dr. SWANSON had an overall industry promotional and research financial footprint of $2,303,952 as recorded in the federal CMS Open Payments database.

$2,286,897 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$17,055 was allocated to sponsored clinical trials and medical research activities.

Dr. SWANSON's primary funding source is GENZYME CORPORATION, which accounts for $475,050 (representing 20.6% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENZYME CORPORATION

Rank 1

$475,050

20.6%

REGENERON HEALTHCARE SOLUTIONS

Rank 2

$473,033

20.5%

LILLY USA

Rank 3

$314,016

13.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.